Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, Chest, vol.141, pp.44-88, 2012. ,
Emergency hospitalizations for adverse drug events in older Americans, N Engl J Med, vol.365, pp.2002-2014, 2011. ,
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes, Thromb Res, vol.132, pp.770-775, 2013. ,
Rivaroxaban versus warfarin in non valvular atrial fibrillation, N Engl J Med, vol.365, pp.883-91, 2011. ,
Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, pp.1139-51, 2009. ,
Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, pp.981-92, 2011. ,
Efficacy and safety of dabigatran etexilate and warfarin in "real world" patients with atrial fibrillation: A prospective nationwide cohort, J Am Coll Cardiol, vol.61, pp.2264-73, 2013. ,
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation, Am J Med, vol.127, pp.650-656, 2014. ,
Dabigatran use in elderly patients with atrial fibrillation, Thromb Haemost, vol.115, pp.152-160, 2016. ,
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation, J Cardiol, vol.69, pp.868-76, 2017. ,
bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation, Stroke, vol.47, pp.441-450, 2016. ,
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation, Circulation, vol.131, pp.157-64, 2015. ,
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants, Eur Heart J Cardiovasc Pharmacother, vol.3, pp.28-36, 2017. ,
Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand, Int J Cardiol, vol.203, pp.746-52, 2016. ,
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation, Thromb Haemost, vol.114, pp.1277-89, 2015. ,
Ischaemic and haemorrhagic stroke associated with non-vitamin k antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: A nationwide cohort study, Eur Heart J, vol.38, pp.907-922, 2017. ,
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system, Thromb Haemost, vol.114, pp.1290-1298, 2015. ,
Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation, J Am Heart Assoc, vol.5, p.3725, 2016. ,
Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in asians with nonvalvular atrial fibrillation, J Am Coll Cardiol, vol.68, pp.1389-1401, 2016. ,
Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the united states: The REVISIT-US study, Curr Med Res Opin, vol.32, issue.12, pp.2047-53, 2016. ,
Bleeding rates in veterans affairs patients with atrial fibrillation who switch from warfarin to dabigatran, Am J Med, vol.127, pp.1179-85, 2014. ,
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients, Curr Med Res Opin, vol.30, pp.1317-1342, 2014. ,
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study, BMJ, vol.350, p.1857, 2015. ,
Risk of bleeding with dabigatran in atrial fibrillation, JAMA Intern Med, vol.175, pp.18-24, 2015. ,
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study, BMJ, vol.350, p.1585, 2015. ,
Effectiveness and safety of dabigatran and warfarin in real-world us patients with non-valvular atrial fibrillation: A retrospective cohort study, J Am Heart Assoc, vol.4, p.1798, 2015. ,
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: A "real-world" observational study in the united states, Int J Clin Pract, vol.70, pp.752-63, 2016. ,
Dabigatran in real-world atrial fibrillation ,
, Meta-analysis of observational comparison studies with vitamin K antagonists, Thromb Haemost, vol.116, pp.754-763, 2016.
Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis, Curr Med Res Opin, vol.32, pp.1117-1137, 2016. ,
Real-world setting comparison of nonvitamin-k antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis, Stroke, vol.48, pp.2494-2503, 2017. ,
Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis, Stroke, vol.49, pp.98-106, 2018. ,
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care, BMJ, vol.362, p.2505, 2018. ,
Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department, BMC Med Res Methodol, vol.19, issue.1, p.194, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02363490
Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide Health Insurance Database (SNIIRAM) linked to emergency departments records within five areas. Rationale and design of SACHA study, Fundam Clin Pharmacol, vol.33, issue.4, pp.443-462, 2019. ,
Schulman S for the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH, J Thromb Haemost, vol.13, pp.2119-2145, 2015. ,
A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, pp.1093-1100, 2010. ,
The best use of the charlson comorbidity index with electronic health care database to predict mortality, Med Care, vol.54, pp.188-94, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01817541
An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res, vol.46, pp.399-424, 2011. ,
Constructing inverse probability weights for marginal structural models, Am J Epidemiol, vol.168, pp.656-64, 2008. ,
Calculating the number needed to treat for trials where the outcome is time to an event, BMJ, vol.319, pp.1492-1497, 1999. ,
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists : a French nationwide propensity-matched cohort study, Circulation, vol.132, pp.1252-1260, 2015. ,
Ascertainment and validation of major bleeding events in a primary care database, Pharmacoepidemiol Drug Saf, 2018. ,
Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study, BMJ, vol.353, p.3189, 2016. ,
Effectiveness and safety of low-dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, vol.356, p.510, 2017. ,
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies, Br J Clin Pharmacol, vol.82, pp.285-300, 2016. ,
Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants, Aliment Pharmacol Ther, vol.42, pp.1239-1288, 2015. ,
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials, Dig Liver Di, vol.47, pp.429-460, 2015. ,
, , vol.658, p.694
, , p.3
, , p.223
, , p.1
, , vol.470, p.966
, , p.9